News & Updates
Showing Pharmacy articles
Showing
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
Lotilaner drops proven safe, effective in Demodex blepharitis
Treatment with lotilaner ophthalmic solution 0.25% twice daily for 6 weeks is well tolerated by patients with Demodex blepharitis and has no serious adverse effects compared to a vehicle control, according to a study. Moreover, use of this drop results in clinically meaningful outcomes.
Water vapor thermal therapy for moderate, severe BPH offers most bang for the buck
In the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore, water vapor thermal therapy (WVTT) is more cost effective than medical management (MM) in the first-line setting based on the common willingness-to-pay threshold of SGD 50,000 per quality-adjusted life-years (QALYs), a study has found.
